1. Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort.
- Author
-
Steindl, Ariane, Schlieter, Franziska, Klikovits, Thomas, Leber, Elena, Gatterbauer, Brigitte, Frischer, Josa M., Dieckmann, Karin, Widhalm, Georg, Zöchbauer-Müller, Sabine, Hoda, Mir Ali Reza, Preusser, Matthias, and Berghoff, Anna S.
- Abstract
Purposes: Brain metastases (BM) are a frequent complication in small cell lung cancer (SCLC), resulting in a reduced survival prognosis. Precise prognostic assessment is an important foundation for treatment decisions and clinical trial planning. Methods: Patients with newly diagnosed SCLC BM were identified from the Vienna Brain Metastasis Registry and evaluated concerning prognostic factors. Results: 489 patients (male 62.2%, female 37.8%; median age 61 years) were included. Neurological symptoms were present in 297/489 (60.7%) patients. A- to oligosymptomatic patients (5 vs. 9 months, p = 0.030) as well as patients with synchronous diagnosis of BM and primary tumor (5 vs. 9 months, p = 0.008) presented with improved overall survival (OS) prognosis. RPA (HR 1.66; 95% CI 1.44–1.91; p < 0.001), GPA (HR 1.65; p < 0.001), DS-GPA (HR 1.60; p < 0.001) and LabBM score (HR 1.69; p < 0.001) were statistically significantly associated with OS. In multivariate analysis, DS-GPA (HR 1.59; p < 0.001), neurological deficits (HR 1.26; p = 0.021) and LabBM score (HR 1.57; p < 0.001) presented with statistical independent association with OS. Conclusion: A- to oligosymptomatic BM as well as synchronous diagnosis of SCLC and BM were associated with improved OS. Established prognostic scores could be validated in this large SCLC BM real-life cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF